Find Novel Drugs for Infections and Infectious Diseases under Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antimicrobial Resistance Antibiotics

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 09, 2020

            Details:

            The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Narsoplimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: OMS721

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            Details:

            Narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S. Army Contracting Command

            Deal Size: $106.3 million Upfront Cash: $53.1 million

            Deal Type: Funding August 26, 2020

            Details:

            In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and therapeutics for COVID-19. This work is in support of the Operation Warp Speed response to the ongoing pandemic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Terra CoV-2 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Terra CoV-2

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Oragenics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 20, 2020

            Details:

            Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics’ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate, Terra CoV-2.